Diaceutics PLC
DXRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 25.77 | 0.12 | 3.09 | 1.57 |
| FCF Yield | -3.76% | -4.84% | 0.44% | -5.88% |
| EV / EBITDA | 34.01 | 24.51 | 12.48 | 28.74 |
| Quality | ||||
| ROIC | -5.34% | -5.13% | 1.65% | 1.57% |
| Gross Margin | 87.91% | 83.15% | 71.97% | 75.78% |
| Cash Conversion Ratio | -0.34 | -0.75 | 7.11 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.14% | 19.34% | 15.39% | 1.23% |
| Free Cash Flow Growth | -12.33% | -1,374.82% | 105.53% | 16.72% |
| Safety | ||||
| Net Debt / EBITDA | -4.21 | -6.55 | -5.13 | -7.71 |
| Interest Coverage | -45.46 | -45.73 | 4.71 | 6.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 55.56 | 58.60 | 144.46 | 205.21 |